GPC3 and hepatocellular carcinoma: GPC3 elevation can be detected in about 50–60% of AFP-negative HCC patients, which may be related to its specific activation in dedifferentiated tumor cells [39], while elevated DCP is caused by defective carboxylation of specific amino-terminal glutamic acid residues in HCC patients [56].